Summary
- Current Price
- As of today, ONC price is $297.49, up +0.12% on
- Current Price All-Time High
- ONC price is currently -30.26% below its historical high of $426.56 set on
- Market Cap
- ONC current market cap is $33B, up +20.50% over the past 365 days
- PE Ratio
- ONC current PE ratio is 117.92
- Revenue
- ONC current annual revenue is $5.36B, up +40.53% year-over-year
- Next Earnings
- The next earnings release for ONC is on
Profile
| Metric | Value |
|---|---|
| Full Name | BeOne Medicines AG |
| Ticker | NASDAQ: ONC |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | Switzerland |
| IPO | |
| Indexes | Not included |
| Website | beonemedicines.com |
| Employees | 12,000 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $297.49 | |
| Price, 1D Change | +0.12% | |
| Market Cap | $33B | |
| - | ||
| PE Ratio | 117.92 | |
| Beta | 0.70 | |
| Revenue | $5B | |
| Revenue, 1Y Change | +40.53% | |
| EPS | $2.54 | |
| EPS, 1Y Change | +141.39% |
Chart
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | BGNE | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $2.54 | |
| EPS Estimate | N/A | $5.67 |
| EPS Est. Change | N/A | +123.64% |
| Revenue | $5.36B | |
| Revenue Estimate | N/A | $6.38B |
| Revenue Est. Change | N/A | +19.16% |
| Current Price | $297.49 | |
| Price Target | - | $405.07 |
| Price Tgt. Change | - | +36.16% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$5.69 | -$6.13 | -7.72% | |
| $3.33 | $2.54 | -23.74% | |
| $5.67 | N/A | +123.64% | |
| $9.53 | N/A | +275.81% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $3.71B | $3.81B | +2.76% | |
| $5.30B | $5.36B | +1.12% | |
| $6.38B | N/A | +19.16% | |
| $7.35B | N/A | +37.15% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +17.05% | |
| Price, 3Y | +19.10% | |
| Market Cap, 1Y | +20.50% | |
| Market Cap, 3Y | +26.60% | |
| Revenue, 1Y | +40.53% | |
| Revenue, 3Y | +278.35% | |
| EPS, 1Y | +141.39% | |
| EPS, 3Y | +113.05% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Date | Value |
|---|---|---|
| Current Price | $297.49 | |
| SMA 200 | $320.59 | |
| SMA 200 vs Price | +7.77% | |
| SMA 50 | $301.78 | |
| SMA 50 vs Price | +1.44% | |
| Beta | 0.70 | |
| ATR | $7.84 | |
| 14-Day RSI | 45.17 | |
| 10-Day Volatility | 26.22% | |
| 1-Year Volatility | 41.34% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $5.36B | |
| EPS | $2.54 | |
| Gross Profit | $0.00 | |
| Gross Margin | 85.28% | |
| Operating Profit | $448.32M | |
| Operating Margin | 8.37% | |
| Net Income | $287.69M | |
| Net Margin | 5.37% | |
| EBITDA | $590.38M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.46 | |
| 3.41 | ||
| 3.08 | ||
| - | ||
| 7 | ||
| 5.04 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 117.92 | |
| 6.17 | ||
| 8.24 | ||
| 51.60 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $4.01B | |
| $4.59B | ||
| $8.23B | ||
| $6.23B | ||
| $3.84B | ||
| $1.83B | ||
| Total Debt | $2.00B | |
| $134.71M | ||
| $479.04M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $5.07B | ||
| $4.12B | ||
| $788.63M | ||
| $0.00 | ||
| $142.06M | ||
| $0.00 | ||
| $130.26M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| $1.13B | ||
| -$276.89M | ||
| $1.06B | ||
| Capex | $206.38M | |
| $924.18M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wells Fargo | ||
| Wolfe Research | ||
| Jefferies | → | |
| Truist Securities | → | |
| RBC Capital | → | |
| Guggenheim | → | |
| Barclays | → | |
| Barclays | → | |
| Truist Securities | ||
| RBC Capital | → |
Analyst sentiment
Institutional ownership
Screeners with ONC
FAQ
What is the ticker symbol for BeOne Medicines AG?
The ticker symbol for BeOne Medicines AG is NASDAQ:ONC
Does BeOne Medicines AG pay dividends?
No, BeOne Medicines AG does not pay dividends
What sector is BeOne Medicines AG in?
BeOne Medicines AG is in the Healthcare sector
What industry is BeOne Medicines AG in?
BeOne Medicines AG is in the Biotechnology industry
What country is BeOne Medicines AG based in?
BeOne Medicines AG is headquartered in Switzerland
When did BeOne Medicines AG go public?
BeOne Medicines AG initial public offering (IPO) was on February 2, 2016
Is BeOne Medicines AG in the S&P 500?
No, BeOne Medicines AG is not included in the S&P 500 index
Is BeOne Medicines AG in the NASDAQ 100?
No, BeOne Medicines AG is not included in the NASDAQ 100 index
Is BeOne Medicines AG in the Dow Jones?
No, BeOne Medicines AG is not included in the Dow Jones index
When was BeOne Medicines AG last earnings report?
BeOne Medicines AG's most recent earnings report was on February 26, 2026
When does BeOne Medicines AG report earnings?
The next expected earnings date for BeOne Medicines AG is May 6, 2026
Data Sources & References
- ONC Official Website beonemedicines.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1651308/000162828026011946/0001628280-26-011946-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1651308/000162828026011946/0001628280-26-011946-index.htm
- ONC Profile on Yahoo Finance finance.yahoo.com/quote/ONC
- ONC Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/onc